Eisai Co. Ltd. (ESAIY PINK) stock market data APIs
$6.6433
0.02(0.3%)
as of July 10, 2026
Try our APIs with
free plan!
Eisai Co. Ltd. Financial Data Overview
Price chart is built with
Anychart
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Prev. Close
6.6433
Open
6.6439
High
6.6446
Low
6.6284
52 wk Range
5.687-8.3972
Market Cap
7 417 M
P/E Ratio
31.2857
Shares Outstanding
1 129 M
Revenue
825 378 M
EPS
-0.0184
Dividends (Yield)
0.0386
Beta
-0.072
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eisai Co. Ltd. data using free add-ons & libraries
Get Eisai Co. Ltd. Fundamental Data
Eisai Co. Ltd. Fundamental data includes:
- Net Revenue: 825 378 M
- EBITDA: 83 689 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eisai Co. Ltd. News
New
Is Nuvation Bio’s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative?
In late June 2026, Nuvation Bio announced that partner Eisai's Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non-small cell lung cancer was validated by the U.K. MHRA...
New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026
STOCKHOLM, June 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's As...
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
Biogen BIIB is in the midst of a major portfolio transition. The company is seeing declining sales of its key multiple sclerosis ("MS") drugs like Tecfidera and Tysabri and spinal muscular atrophy (SM...
Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C
-- $135 million equity financing with participation from leading specialist investors, corporate investors, and long-term growth partners, including Wellington Partners, JIC Venture Growth Investments...
Get Eisai Co. Ltd. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
